Sector: Life Sciences

Latest content

“Every crisis brings about innovation" – how the vaccine race is transforming biopharma IP

From greater respect for researchers to a fresh focus on compulsory licences, IAM’s Global Leaders share their views on how the life sciences space has been changed by the quest for covid-19 vaccines

24 November 2021

How to deal with China's new crackdown on bad-faith patent filings and other examination changes

The Long Read: New guidelines in the works at the CNIPA will continue the fight against 'irregular' applications, make utility models harder to get and heighten the risk of litigation in the software space, write Aaron Wininger of Schwegman Lundberg & Woessner, PA and Austin Chang of Beijing East IP

24 November 2021

Novo Nordisk’s $3.3 billion Dicerna purchase shows booming RNA IP market

Danish company makes its biggest-ever acquisition in an area where demand for assets is growing rapidly

23 November 2021

Why CNIPA could be the go-to venue for Chinese patent linkage plaintiffs

Pharma patentees face difficult choices under the country’s new early dispute resolution framework

19 November 2021

Nobel laureate’s troubles are a cautionary tale about the importance of university tech-transfer support

Tasuku Honjo’s recent patent battles highlight the potential IP dangers of academic collaborations

18 November 2021

Patent suits decline in Dusseldorf and Mannheim, but Munich’s docket is on the rise

Germany is Europe’s biggest and most active litigation forum, but subtle differences in case law and proceedings mean that plaintiffs have important choices to make about where to file their suits

16 November 2021

Four things to watch as China’s first patent linkage litigation is filed

Beijing IP Court lawsuit launched by Japan’s Chugai Pharmaceutical will be inaugural test of the new system, and possible procedural issues are already appearing

16 November 2021

A multi-million-dollar patent damages win for J&J in China is good news for foreign rights holders

US company’s subsidiary secures major award against a local infringer at the Supreme People’s Court

12 November 2021

Moderna on IP collision course with US government

The company is at loggerheads with National Institutes of Health over inventorship of crucial covid vaccine technology

11 November 2021

Dim prospects for industry 101 compromise as US Congress looks at eligibility once more

People involved in previous reform efforts say that passing any legislation will be tough as stakeholders are still years away from agreement

09 November 2021

Get unlimited access to all IAM content